Overexpression of MiR-671-5p Indicates a Poor Prognosis in Colon Cancer and Accelerates Proliferation, Migration, and Invasion of Colon Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Nov 6

PMID 31686843

Citations 18

Authors

Wei Jin

Jinsheng Shi

Meiqin Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Colon cancer is one of the common malignancies worldwide, and many genes, including microRNAs (miRNAs), have been demonstrated that associated with progression of various diseases, including cancers. The aim of this study is to investigate the potential role of miR-671-5p in colon cancer.

Patients And Methods: Reverse transcription-quantitative polymerase chain reaction (qRT-PCR) was performed to detect the expression levels of miR-671-5p in 115 paired colon cancer tissues and adjacent normal tissues, as well as in colon cancer cells. Kaplan-Meier curve and Cox regression analyses were used to estimate the prognostic significance of miR-671-5p in colon cancer. CCK-8 assay, colony-formation assay, Transwell migration and invasion assays were used to evaluate the effects of miR-671-5p on cell proliferation, migration, and invasion in colon cancer.

Results: We found that miR-671-5p expression was increased in colon cancer tissues and cell lines. Overexpression of miR-671-5p was found associated with lymph node metastasis, TNM stage, and poor overall survival of patients with colon cancer. By exploiting miR-671-5p mimics and inhibitors, miR-671-5p overexpression significantly increased cell proliferation, migration, and invasion, while downregulation of miR-671-5p inhibited proliferation, migration, and invasion of colon cancer cells.

Conclusion: Taken together, miR-671-5p may act as an oncogene in colon cancer and promote proliferation, migration, and invasion of colon cancer cells by targeting TRIM67. And it may be a promising prognostic biomarker and therapeutic application for colon cancer treatment.

Citing Articles

Hsa_circ_0000423 promotes colorectal cancer EMT and immune escape by competitive adsorption of miR-369-3p mediating CCND1 expression.

Huang T, Jiang K, Li L, Li G, Cao Y, Huang X Discov Oncol. 2024; 15(1):634.

PMID: 39520607 PMC: 11550305. DOI: 10.1007/s12672-024-01501-3.

Circular RNA circARHGEF28 inhibited the progression of prostate cancer via the miR-671-5p/LGALS3BP/NF-κB axis.

Guo K, Shi J, Tang Z, Lai C, Liu C, Li K Cancer Sci. 2023; 114(7):2907-2919.

PMID: 37186007 PMC: 10323094. DOI: 10.1111/cas.15820.

miR-3133 is an unfavorable prognosis factor and tumor suppressor in colon cancer.

Gao H, Zhang C Funct Integr Genomics. 2023; 23(2):132.

PMID: 37079151 DOI: 10.1007/s10142-023-01059-3.

Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape.

Gu J, Chen J, Xiang S, Zhou X, Li J J Adv Res. 2023; 54:147-179.

PMID: 36736694 PMC: 10703639. DOI: 10.1016/j.jare.2023.01.011.

A review on the role of miR-671 in human disorders.

Ghafouri-Fard S, Askari A, Hussen B, Rasul M, Hatamian S, Taheri M Front Mol Biosci. 2022; 9:1077968.

PMID: 36545507 PMC: 9760869. DOI: 10.3389/fmolb.2022.1077968.

References

Guo Y, Pang Y, Gao X, Zhao M, Zhang X, Zhang H . MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomark. 2016; 18(1):1-9. DOI: 10.3233/CBM-160650. View

Cheng G . Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2014; 81:75-93. DOI: 10.1016/j.addr.2014.09.001. View

Freeman H . Early stage colon cancer. World J Gastroenterol. 2014; 19(46):8468-73. PMC: 3870492. DOI: 10.3748/wjg.v19.i46.8468. View

Barbagallo D, Condorelli A, Ragusa M, Salito L, Sammito M, Banelli B . Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme. Oncotarget. 2015; 7(4):4746-59. PMC: 4826240. DOI: 10.18632/oncotarget.6621. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Bi D, Yin C, Zhang X, Yang N, Xu J . MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer. Oncol Rep. 2016; 35(5):2873-9. DOI: 10.3892/or.2016.4631. View

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

Yu Y, Wang Z, Sun D, Zhou X, Wei X, Hou W . miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6. Eur J Pharmacol. 2018; 823:65-71. DOI: 10.1016/j.ejphar.2018.01.016. View

Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View

10.

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A . A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011; 83(4):1113-9. DOI: 10.1016/j.ijrobp.2011.09.030. View

11.

Cao H, Huang S, Liu A, Chen Z . Up-regulated expression of miR-155 in human colonic cancer. J Cancer Res Ther. 2018; 14(3):604-607. DOI: 10.4103/0973-1482.175432. View

12.

Wahid F, Khan T, Kim Y . MicroRNA and diseases: therapeutic potential as new generation of drugs. Biochimie. 2014; 104:12-26. DOI: 10.1016/j.biochi.2014.05.004. View

13.

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

14.

Yoshikawa T, Wu J, Otsuka M, Kishikawa T, Suzuki N, Takata A . Repression of MicroRNA Function Mediates Inflammation-associated Colon Tumorigenesis. Gastroenterology. 2016; 152(3):631-643. DOI: 10.1053/j.gastro.2016.10.043. View

15.

Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K . miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2015; 7(1):293-307. PMC: 4807999. DOI: 10.18632/oncotarget.6344. View

16.

Sun S, Zhang G, Wu Z, Shi W, Yang B, Li Y . MicroRNA-302a functions as a putative tumor suppressor in colon cancer by targeting Akt. PLoS One. 2014; 9(12):e115980. PMC: 4277419. DOI: 10.1371/journal.pone.0115980. View

17.

Hatakeyama S . TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends Biochem Sci. 2017; 42(4):297-311. DOI: 10.1016/j.tibs.2017.01.002. View

18.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

19.

Liu R, Chen Y, Shou T, Hu J, Chen J, Qing C . TRIM67 promotes NF‑κB pathway and cell apoptosis in GA‑13315‑treated lung cancer cells. Mol Med Rep. 2019; 20(3):2936-2944. DOI: 10.3892/mmr.2019.10509. View

20.

Zhu Y, Zhang X, Qi M, Zhang Y, Ding F . miR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling. J Gastroenterol Hepatol. 2019; 34(12):2126-2134. DOI: 10.1111/jgh.14697. View